IP Library Granted Patent US 8,685,432
Granted Patent B2
US 8,685,432 · App. 12/409,261 · Granted Apr 1, 2014

Controlled release tissue graft combination biomaterials

Inventors: Bruce G. Evans (Sandy, UT); David Christopher Evans (Sandy, UT); Paul C. Hogrebe (Salt Lake City, UT); David W. Grainger (Salt Lake City, UT); Amanda Elaine Brooks (Highland, UT)
Assignee: University of Utah Research Foundation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,685,432
App. No.
12/409,261
Granted
Apr 1, 2014
Kind
B2
Abstract

In one aspect, the invention relates to tissue graft combination biomaterials capable of controlled release of bioactive agents or pharmaceutically active agents through a rate-controlling polymer coating encapsulating the graft material, methods for preparing same, methods of controlled release using same, and methods for treating tissue defects. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Claims (10)

1. A bone graft combination biomaterial comprising:

a. a biocompatible, osteoconductive, porous substrate, wherein the substrate comprises a material selected from the group consisting of an allograft bone and an alloplastic material, wherein the substrate is devoid of collagen and wherein the substrate comprises in its pores demineralized bone matrix and a first antimicrobial agent; and

b. a film coating on the substrate surface, the coating comprising a degradable rate controlling polymer, wherein said polymer is polycaprolactone having a molecular weight from about 10 kD to about 200 kD , admixed with at least one second antimicrobial agent microencapsulated in microspheres or nanoencapsulated in nanospheres, wherein the first antimicrobial agent and the second antimicrobial agent can be the same or different,

and wherein the polycaprolactone has a structure and a molecular weight selected to degrade over a time period of about six weeks when implanted within a subject and thereby release the agent over the time period.

2. The combination biomaterial of claim 1 , wherein the substrate further comprises bone powder.

3. The combination biomaterial of claim 1 , wherein the polycaprolactone has a molecular weight from about 10 kD to about 100kD.

4. The combination biomaterial of claim 1 , wherein the alloplastic material is (tri)calcium phosphate.

5. The combination biomaterial of claim 1 , wherein the alloplastic material is hydroxyapatite.

6. The combination biomaterial of claim 1 , wherein the alloplastic material is calcium sulfate.

7. The combination biomaterial of claim 1 , wherein the alloplastic material is calcium phosphate.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 27, 2009
From: HOGREBE, PAUL C.; GRAINGER, DAVID W.; EVANS, BRUCE G.; EVANS, DAVID CHRISTOPHER; BROOKS, AMANDA ELAINE
To: UNIVERSITY OF UTAH
Reel/Frame 023154/0434 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 27, 2009
From: UNIVERSITY OF UTAH
To: UNIVERSITY OF UTAH RESEARCH FOUNDATION
Reel/Frame 023154/0534 →
Continuity (2)
Provisional Application 61070638 · Mar 25, 2008
Related Publication 20090324683A1 · Dec 31, 2009